<?xml version='1.0' encoding='utf-8'?>
<document id="27474787"><sentence text="Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys."><entity charOffset="136-146" id="DDI-PubMed.27474787.s1.e0" text="amiodarone" /></sentence><sentence text="In 2015, European and U" /><sentence text="S" /><sentence text=" health agencies issued warning letters in response to 9 reported clinical cases of severe bradycardia/bradyarrhythmia in hepatitis C virus (HCV)-infected patients treated with sofosbuvir (SOF) in combination with other direct acting antivirals (DAAs) and the antiarrhythmic drug, amiodarone (AMIO)"><entity charOffset="177-187" id="DDI-PubMed.27474787.s4.e0" text="sofosbuvir" /><entity charOffset="189-192" id="DDI-PubMed.27474787.s4.e1" text="SOF" /><entity charOffset="281-291" id="DDI-PubMed.27474787.s4.e2" text="amiodarone" /><entity charOffset="293-297" id="DDI-PubMed.27474787.s4.e3" text="AMIO" /><pair ddi="false" e1="DDI-PubMed.27474787.s4.e0" e2="DDI-PubMed.27474787.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27474787.s4.e0" e2="DDI-PubMed.27474787.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27474787.s4.e0" e2="DDI-PubMed.27474787.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27474787.s4.e0" e2="DDI-PubMed.27474787.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27474787.s4.e1" e2="DDI-PubMed.27474787.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27474787.s4.e1" e2="DDI-PubMed.27474787.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27474787.s4.e1" e2="DDI-PubMed.27474787.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27474787.s4.e2" e2="DDI-PubMed.27474787.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27474787.s4.e2" e2="DDI-PubMed.27474787.s4.e3" /></sentence><sentence text=" We utilized preclinical in vivo models to better understand this cardiac effect, the potential pharmacological mechanism(s), and to identify a clinically translatable model to assess the drug-drug interaction (DDI) cardiac risk of current and future HCV inhibitors" /><sentence text=" An anesthetized guinea pig model was used to elicit a SOF+AMIO-dependent bradycardia"><entity charOffset="55-58" id="DDI-PubMed.27474787.s6.e0" text="SOF" /><entity charOffset="59-62" id="DDI-PubMed.27474787.s6.e1" text="AMIO" /><pair ddi="false" e1="DDI-PubMed.27474787.s6.e0" e2="DDI-PubMed.27474787.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27474787.s6.e0" e2="DDI-PubMed.27474787.s6.e1" /></sentence><sentence text=" Detailed cardiac electrophysiological studies in this species revealed SOF+AMIO-dependent selective nodal dysfunction, with initial, larger effects on the sinoatrial node"><entity charOffset="72-75" id="DDI-PubMed.27474787.s7.e0" text="SOF" /><entity charOffset="76-79" id="DDI-PubMed.27474787.s7.e1" text="AMIO" /><pair ddi="false" e1="DDI-PubMed.27474787.s7.e0" e2="DDI-PubMed.27474787.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27474787.s7.e0" e2="DDI-PubMed.27474787.s7.e1" /></sentence><sentence text=" Further studies in conscious, rhesus monkeys revealed an emergent bradycardia and bradyarrhythmia in 3 of 4 monkeys administered SOF+AMIO, effects not observed with either agent alone"><entity charOffset="130-138" id="DDI-PubMed.27474787.s8.e0" text="SOF+AMIO" /><entity charOffset="134-141" id="DDI-PubMed.27474787.s8.e1" text="AMIO" /><pair ddi="false" e1="DDI-PubMed.27474787.s8.e0" e2="DDI-PubMed.27474787.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27474787.s8.e0" e2="DDI-PubMed.27474787.s8.e1" /></sentence><sentence text=" Morever, bradycardia and bradyarrhythmia were not observed in rhesus monkeys when intravenous infusion of MK-3682 was completed after AMIO pretreatment"><entity charOffset="135-138" id="DDI-PubMed.27474787.s9.e0" text="AMIO" /></sentence><sentence text="" /><sentence text="These are the first preclinical in vivo experiments reported to replicate the severe clinical SOF+AMIO cardiac DDI and provide potential in vivo mechanism of action"><entity charOffset="94-97" id="DDI-PubMed.27474787.s11.e0" text="SOF" /><entity charOffset="98-101" id="DDI-PubMed.27474787.s11.e1" text="AMIO" /><pair ddi="false" e1="DDI-PubMed.27474787.s11.e0" e2="DDI-PubMed.27474787.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27474787.s11.e0" e2="DDI-PubMed.27474787.s11.e1" /></sentence><sentence text=" As such, these data provide a preclinical risk assessment paradigm, including a clinically relevant nonhuman primate model, with which to better understand cardiovascular DDI risk for this therapeutic class" /><sentence text=" Furthermore, these studies suggest that not all HCV DAAs and, in particular, not all HCV nonstructural protein 5B inhibitors may exhibit this cardiac DDI with amiodarone"><entity charOffset="160-170" id="DDI-PubMed.27474787.s13.e0" text="amiodarone" /></sentence><sentence text=" Given the selective in vivo cardiac electrophysiological effect, these data enable targeted cellular/molecular mechanistic studies to more precisely identify cell types, receptors, and/or ion channels responsible for the clinical DDI" /><sentence text=" (Hepatology 2016;64:1430-1441)" /><sentence text="" /></document>